BMPR1A/ALK-3 hFc Chimera, Canine
BMPR1A/ALK-3 HFc Chimera, Canine

Measured by its ability to inhibit rhBMP4-induced alkaline phosphatase production by ATDC5 cells. The ED50 for this effect is typically 0.5 - 2.5 μg/mL in the presence of 50 ng/mL of recombinant human BMP4.

BMPR1A/ALK-3 HFc Chimera, Canine

The purity of BMPR1A/ALK-3 hFc Chimera, Canine is greater than 95% as determined by SEC-HPLC.

BMPR1A/ALK-3 HFc Chimera, Canine

BMPR1A/ALK-3 hFc Chimera, Canine on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

BMPR1A/ALK-3 hFc Chimera, Canine

The type IA bone morphogenetic protein receptor (Bmpr1a), encoded by 11 exons and spanning about 40 kb on chromosome 14 in mice and chromosome 10 in human (Derynck & Feng, 1997; Mishina, Hanks, Miura, Tallquist, & Behringer, 2002), is an essential receptor for BMP signaling.
Z04690
¥80,213.00

Ask us a question
Product Introduction
Species Canine
Protein Construction
BMPR1A/ALK-3 (Gln24-Arg152)
Accession # NP_001138622.1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its ability to inhibit rhBMP4­induced alkaline phosphatase production by ATDC5 cells. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 40.94 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • BMPR1A/ALK-3 HFc Chimera, Canine
    • BMPR1A/ALK-3 HFc Chimera, Canine

    Measured by its ability to inhibit rhBMP4-induced alkaline phosphatase production by ATDC5 cells. The ED50 for this effect is typically 0.5 - 2.5 μg/mL in the presence of 50 ng/mL of recombinant human BMP4.

  • BMPR1A/ALK-3 HFc Chimera, Canine
    • BMPR1A/ALK-3 HFc Chimera, Canine

    The purity of BMPR1A/ALK-3 hFc Chimera, Canine is greater than 95% as determined by SEC-HPLC.

  • BMPR1A/ALK-3 HFc Chimera, Canine
    • BMPR1A/ALK-3 HFc Chimera, Canine

    BMPR1A/ALK-3 hFc Chimera, Canine on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The type IA bone morphogenetic protein receptor (Bmpr1a), encoded by 11 exons and spanning about 40 kb on chromosome 14 in mice and chromosome 10 in human (Derynck & Feng, 1997; Mishina, Hanks, Miura, Tallquist, & Behringer, 2002), is an essential receptor for BMP signaling.
Synonyms BMPR1A; ALK-3; ALK3; ALK 3

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.